$75.30
0.350.47%
À la fermeture: -
$75.30
N/A
Après les heures de négociation: 4:00 PM EDT
Comments
Loading...
Évaluations des analystes, objectifs de prix, prévision
PTC Therapeutics Inc a un objectif de cours consensuel de $66.6 basé sur les évaluations de 21 analystes. Le plus élevé est $118, publié par Cantor Fitzgerald le septembre 3, 2025. Le plus bas est $17, publié par Citigroup le octobre 27, 2023. Les 3 évaluations d’analystes les plus récentes ont été publiées par Barclays, Citigroup et TD Cowen le novembre 6, 2025, novembre 5, 2025 et novembre 5, 2025, respectivement. Avec un objectif de cours moyen de $68.67 entre Barclays, Citigroup et TD Cowen, il existe une variation implicite de -8.81% downside pour PTC Therapeutics Inc selon ces dernières évaluations d’analystes.
Sociétés d'analyse émettant des recommandations1
Barclays
Citigroup
TD Cowen
RBC Capital
Goldman Sachs
1calculé à partir des notes des analystes
Notes d'analystes pour PTC Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/06/2025 | -9.69% | Barclays | $46 → $68 | Maintains | Equal-Weight | |||
11/05/2025 | -0.4% | Citigroup | $50 → $75 | Maintains | Neutral | |||
11/05/2025 | -16.33% | TD Cowen | $50 → $63 | Maintains | Hold | |||
11/05/2025 | 8.9% | RBC Capital | $70 → $82 | Maintains | Outperform | |||
11/05/2025 | -33.6% | Goldman Sachs | $44 → $50 | Maintains | Sell | |||
11/05/2025 | 23.51% | Wells Fargo | $73 → $93 | Maintains | Overweight | |||
10/28/2025 | 2.26% | Jefferies | $63 → $77 | Maintains | Buy | |||
09/03/2025 | 56.71% | Cantor Fitzgerald | $118 → $118 | Reiterates | Overweight → Overweight | |||
08/20/2025 | -3.05% | Wells Fargo | $79 → $73 | Maintains | Overweight | |||
08/20/2025 | -5.71% | Morgan Stanley | $76 → $71 | Maintains | Overweight | |||
08/20/2025 | 0.93% | B of A Securities | $82 → $76 | Maintains | Buy | |||
08/08/2025 | 0.93% | Morgan Stanley | $70 → $76 | Maintains | Overweight | |||
08/08/2025 | -16.33% | RBC Capital | $60 → $63 | Maintains | Outperform | |||
08/08/2025 | 4.91% | Wells Fargo | $78 → $79 | Maintains | Overweight | |||
07/29/2025 | 14.21% | Truist Securities | $80 → $86 | Maintains | Buy | |||
07/29/2025 | 11.55% | B of A Securities | $68 → $84 | Maintains | Buy | |||
07/29/2025 | -38.91% | Barclays | $42 → $46 | Maintains | Equal-Weight | |||
07/29/2025 | 3.59% | Wells Fargo | $74 → $78 | Maintains | Overweight | |||
07/29/2025 | 59.36% | Cantor Fitzgerald | $112 → $120 | Maintains | Overweight | |||
07/29/2025 | 6.24% | UBS | $71 → $80 | Maintains | Buy | |||
07/28/2025 | -33.6% | Citigroup | $40 → $50 | Maintains | Neutral | |||
06/17/2025 | 6.24% | Truist Securities | → $80 | Initiates | → Buy | |||
05/27/2025 | -1.73% | Wells Fargo | $68 → $74 | Maintains | Overweight | |||
05/09/2025 | -9.69% | B of A Securities | $55 → $68 | Upgrade | Neutral → Buy | |||
05/08/2025 | -44.22% | Barclays | $56 → $42 | Maintains | Equal-Weight | |||
05/07/2025 | -12.35% | Baird | $70 → $66 | Maintains | Outperform | |||
05/07/2025 | -22.97% | RBC Capital | $57 → $58 | Maintains | Outperform | |||
05/07/2025 | 48.74% | Cantor Fitzgerald | $113 → $112 | Maintains | Overweight | |||
05/07/2025 | -11.02% | JP Morgan | $75 → $67 | Maintains | Overweight | |||
05/07/2025 | -46.88% | Citigroup | $50 → $40 | Upgrade | Sell → Neutral | |||
04/22/2025 | -13.68% | RBC Capital | $65 → $65 | Reiterates | Outperform → Outperform | |||
03/31/2025 | -0.4% | JP Morgan | $78 → $75 | Maintains | Overweight | |||
03/14/2025 | 3.59% | JP Morgan | $72 → $78 | Maintains | Overweight | |||
03/11/2025 | -26.96% | B of A Securities | $41 → $55 | Upgrade | Underperform → Neutral | |||
03/07/2025 | -26.96% | Scotiabank | → $55 | Initiates | → Sector Perform | |||
03/07/2025 | -7.04% | Morgan Stanley | $67 → $70 | Assumes | → Overweight | |||
02/28/2025 | -4.38% | JP Morgan | $74 → $72 | Maintains | Overweight | |||
02/18/2025 | -16.33% | RBC Capital | $60 → $63 | Maintains | Outperform | |||
02/12/2025 | -40.24% | Citigroup | $32 → $45 | Maintains | Sell | |||
02/03/2025 | 50.07% | Cantor Fitzgerald | $76 → $113 | Maintains | Overweight | |||
01/15/2025 | 0.93% | Cantor Fitzgerald | $80 → $76 | Maintains | Overweight | |||
12/13/2024 | -11.02% | Morgan Stanley | $45 → $67 | Upgrade | Equal-Weight → Overweight | |||
12/04/2024 | -57.5% | Citigroup | $26 → $32 | Maintains | Sell | |||
12/04/2024 | -44.22% | Goldman Sachs | $32 → $42 | Maintains | Sell | |||
12/03/2024 | -5.71% | UBS | $47 → $71 | Maintains | Buy | |||
12/03/2024 | -7.04% | Baird | $52 → $70 | Maintains | Outperform | |||
12/03/2024 | -25.63% | Barclays | $45 → $56 | Maintains | Equal-Weight | |||
11/27/2024 | -30.94% | Baird | $48 → $52 | Maintains | Outperform | |||
11/26/2024 | -9.69% | Wells Fargo | $56 → $68 | Maintains | Overweight | |||
11/19/2024 | -17.66% | JP Morgan | $51 → $62 | Maintains | Overweight | |||
11/14/2024 | -40.24% | Barclays | $43 → $45 | Maintains | Equal-Weight | |||
11/11/2024 | -42.9% | Barclays | $31 → $43 | Maintains | Equal-Weight | |||
11/08/2024 | -36.25% | Baird | $44 → $48 | Maintains | Outperform | |||
10/11/2024 | -40.24% | Morgan Stanley | $32 → $45 | Maintains | Equal-Weight | |||
10/08/2024 | -41.57% | Baird | $44 → $44 | Reiterates | Outperform → Outperform | |||
10/04/2024 | -54.85% | RBC Capital | $32 → $34 | Maintains | Sector Perform | |||
09/20/2024 | -15.01% | Cantor Fitzgerald | $64 → $64 | Reiterates | Overweight → Overweight | |||
09/17/2024 | -15.01% | Cantor Fitzgerald | $64 → $64 | Reiterates | Overweight → Overweight | |||
09/04/2024 | -41.57% | Baird | → $44 | Initiates | → Outperform | |||
08/26/2024 | -37.58% | UBS | → $47 | Upgrade | Neutral → Buy | |||
08/21/2024 | -15.01% | Cantor Fitzgerald | $64 → $64 | Reiterates | Overweight → Overweight | |||
08/09/2024 | -15.01% | Cantor Fitzgerald | $62 → $64 | Maintains | Overweight | |||
08/09/2024 | -58.83% | Barclays | $25 → $31 | Maintains | Equal-Weight | |||
07/16/2024 | -17.66% | Cantor Fitzgerald | $62 → $62 | Reiterates | Overweight → Overweight | |||
07/12/2024 | -57.5% | Morgan Stanley | $30 → $32 | Maintains | Equal-Weight | |||
07/01/2024 | -17.66% | Cantor Fitzgerald | $52 → $62 | Maintains | Overweight | |||
06/21/2024 | -57.5% | B of A Securities | $25 → $32 | Maintains | Underperform | |||
06/20/2024 | -29.61% | JP Morgan | $53 → $53 | Maintains | Overweight | |||
05/28/2024 | -57.5% | Goldman Sachs | $18 → $32 | Maintains | Sell | |||
05/21/2024 | -65.47% | Citigroup | $18 → $26 | Maintains | Sell | |||
05/21/2024 | -29.61% | JP Morgan | $43 → $53 | Maintains | Overweight | |||
05/21/2024 | -57.5% | Goldman Sachs | $18 → $32 | Maintains | Sell | |||
05/20/2024 | -38.91% | Jefferies | $35 → $46 | Maintains | Buy | |||
04/29/2024 | -60.16% | Morgan Stanley | $28 → $30 | Upgrade | Underweight → Equal-Weight | |||
04/12/2024 | -40.24% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
03/20/2024 | -53.52% | Jefferies | $33 → $35 | Maintains | Buy | |||
03/08/2024 | -62.82% | RBC Capital | $28 → $28 | Reiterates | Sector Perform → Sector Perform | |||
03/01/2024 | -40.24% | Cantor Fitzgerald | $45 → $45 | Reiterates | Overweight → Overweight | |||
03/01/2024 | -62.82% | RBC Capital | $22 → $28 | Maintains | Sector Perform | |||
03/01/2024 | -60.16% | TD Cowen | $32 → $30 | Maintains | Market Perform | |||
01/26/2024 | -70.78% | RBC Capital | $27 → $22 | Maintains | Sector Perform | |||
01/26/2024 | -40.24% | Cantor Fitzgerald | $51 → $45 | Maintains | Overweight | |||
12/19/2023 | -62.82% | Morgan Stanley | → $28 | Downgrade | Equal-Weight → Underweight | |||
12/18/2023 | -32.27% | Cantor Fitzgerald | $51 → $51 | Reiterates | Overweight → Overweight | |||
12/18/2023 | -76.1% | Goldman Sachs | $20 → $18 | Maintains | Sell | |||
11/20/2023 | -32.27% | Cantor Fitzgerald | → $51 | Reiterates | Overweight → Overweight | |||
10/27/2023 | -62.82% | Morgan Stanley | $31 → $28 | Maintains | Equal-Weight | |||
10/27/2023 | -66.8% | Barclays | $26 → $25 | Maintains | Equal-Weight | |||
10/27/2023 | -77.42% | Citigroup | $29 → $17 | Downgrade | Neutral → Sell | |||
10/06/2023 | -66.8% | Truist Securities | → $25 | Downgrade | Buy → Hold | |||
09/19/2023 | -40.24% | Truist Securities | → $45 | Reiterates | Buy → Buy | |||
09/19/2023 | -69.46% | B of A Securities | $43 → $23 | Maintains | Underperform | |||
09/18/2023 | -40.24% | Truist Securities | $60 → $45 | Maintains | Buy | |||
09/18/2023 | -65.47% | Barclays | $44 → $26 | Maintains | Equal-Weight | |||
09/18/2023 | -58.83% | Morgan Stanley | $47 → $31 | Maintains | Equal-Weight | |||
09/18/2023 | -70.78% | Goldman Sachs | $35 → $22 | Maintains | Sell | |||
09/18/2023 | -65.47% | RBC Capital | $49 → $26 | Maintains | Sector Perform | |||
09/18/2023 | -61.49% | Citigroup | $55 → $29 | Downgrade | Buy → Neutral | |||
09/18/2023 | — | Raymond James | — | Downgrade | Outperform → Underperform | |||
09/15/2023 | — | Raymond James | — | Downgrade | Outperform → Underperform |
FAQ
Quel est le cours indicatif de l'action PTC Therapeutics (PTCT) ?
Le dernier objectif de prix pour PTC Therapeutics (NASDAQ:PTCT) a été rapporté par Barclays le novembre 6, 2025. Le cabinet d'analystes a fixé un objectif de prix pour $68.00 s'attendant à ce que PTCT se fall dans les 12 prochains mois (un possible changement de -9.69% downside). 50 cabinets d'analystes ont rapporté des notes au cours de la dernière année.
Quelle est la note d'analyste la plus récente pour PTC Therapeutics (PTCT) ?
La dernière note d'analyste pour PTC Therapeutics (NASDAQ:PTCT) a été fournie par Barclays, et PTC Therapeutics maintenu leur note equal-weight.
Quand a eu lieu la dernière mise à niveau pour PTC Therapeutics (PTCT) ?
La dernière amélioration pour PTC Therapeutics Inc a eu lieu le mai 9, 2025 lorsque B of A Securities a augmenté leur objectif de prix à $68. B of A Securities avait précédemment a neutral pour PTC Therapeutics Inc.
Quand a eu lieu la dernière dégradation pour PTC Therapeutics (PTCT) ?
La dernière réduction pour PTC Therapeutics Inc a eu lieu le décembre 19, 2023 lorsque Morgan Stanley a changé leur objectif de prix de N/A à $28 pour PTC Therapeutics Inc.
Quand la prochaine note d'analyste sera-t-elle publiée ou mise à jour pour PTC Therapeutics (PTCT) ?
Les analystes arrivent à des évaluations d'actions après avoir effectué des recherches approfondies, ce qui inclut l'examen des états financiers publics, la discussion avec les dirigeants et les clients de PTC Therapeutics, et l'écoute des conférences téléphoniques sur les résultats. La plupart des analystes font cela tous les trois mois, vous devriez donc obtenir 4 notes par entreprise par société chaque année. La dernière note pour PTC Therapeutics a été déposée le novembre 6, 2025, donc vous devriez vous attendre à ce que la prochaine note soit disponible vers novembre 6, 2026.
La note d'analyste pour PTC Therapeutics (PTCT) est-elle correcte ?
Bien que les évaluations soient subjectives et changeront, la dernière note de PTC Therapeutics (PTCT) était un maintenu avec un objectif de prix de $46.00 à $68.00. Le prix actuel de PTC Therapeutics (PTCT) est de $75.30, ce qui est out of la fourchette prédite par l'analyste.
Parcourir notes d'analystes et objectifs de cours sur toutes les actions.